← ANALYST RATINGS · TIPRANKS
Nektar Therapeutics (NKTR): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy2 Hold0 Sell
Ratings of 8 analysts in the last 3 months · top analysts only12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $137, the highest $192, the lowest $50.00. The average is +283.4% from the last price of $35.78.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $37.00 → $38.00+2.7% | Hold | +6.2% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $37.00 → $38.00+2.7% | Hold | +6.2% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $37.00 → $38.00+2.7% | Hold | +6.2% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $39.00 → $40.00+2.6% | Hold | +11.8% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $36.00 → $37.00+2.8% | Hold | +3.4% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $39.00 → $38.00−2.6% | Hold | +6.2% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| Unknown Analyst | Leerink Partners | $130 | Buy | +263.3% | Initiated | 12.10.26on TipRanks 08:15 | −3.2%next day −4.8% | ↗ |
| Name not given | — | $53.00 | Hold | +48.1% | Initiated | 11.10.26on TipRanks Oct 12 05:50 | −3.2%next day −4.8% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $178 | Buy | +397.5% | Reiterated | 09.10.26on TipRanks Oct 11 18:55 | +0.3%next day −3.2% · 5 days −11.1% | ↗ |
| Name not given | — | — | Hold | — | Initiated | 08.10.26on TipRanks Oct 11 09:55 | +1.8%next day +0.3% · 5 days −7.3% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $151 | Buy | +322.0% | Reiterated | 05.10.26on TipRanks 05:35 | −3.8%next day −6.0% · 5 days −6.1% | ↗ |
| Unknown Analyst | B. Riley Securities | $150 | Buy | +319.2% | Reiterated | 02.10.26on TipRanks 13:05 | −8.0%next day −3.8% · 5 days −6.7% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $150 | Buy | +319.2% | Reiterated | 01.10.26on TipRanks 14:30 | −22.6%next day −8.0% · 5 days −14.5% | ↗ |
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Buy | — | Reiterated | 01.10.26on TipRanks 12:20 | −22.6%next day −8.0% · 5 days −14.5% | ↗ |
| Arthur He CFA★★★★★★★★★★#323 · hits 58% · avg +36.5% | H.C. Wainwright | $185 | Buy | +417.0% | Reiterated | 01.10.26on TipRanks 08:10 | −22.6%next day −8.0% · 5 days −14.5% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $153 | Buy | +327.6% | Reiterated | 28.09.26on TipRanks 06:55 | +6.6%next day −1.7% · 5 days −31.3% | ↗ |
| Martin Fan★★★★★★★★★★#177 · hits 87% · avg +94.8% | Wedbush | $80.00 → $50.00−37.5% | Hold | +39.7% | Reiterated | 23.09.26on TipRanks 08:12 | −4.7%next day +3.1% · 5 days +5.7% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $65.00 | Hold | +81.7% | Initiated | 21.08.26on TipRanks 06:36 | −1.1%next day −0.2% · 5 days −2.5% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $192 | Buy | +436.6% | Reiterated | 20.08.26on TipRanks 07:15 | −1.2%next day −1.1% · 5 days −1.1% | ↗ |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | — | Buy | — | Reiterated | 13.08.26on TipRanks Aug 17 05:56 | −0.8%next day −3.6% · 5 days +0.1% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $140 | Buy | +291.3% | Reiterated | 08.05.26on TipRanks 08:45 | −2.6%next day −4.1% · 5 days −14.0% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $105 → $150+42.9% | Buy | +319.2% | Reiterated | 23.02.26on TipRanks 08:25 | +0.9%next day −7.8% · 5 days −7.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Nektar Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $140 at a price of $60.55 (+132.1%); now: $132 at $35.78 (+270.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 7 | 7 | 9 | 13 | 12 |
| Buy | 3 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 2 | 1 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-2.07 (from $-3.07 to $-1.71). Last quarter: $-1.23.
Sales
Next quarter’s sales estimate — $10M (from $10M to $11M). Last quarter: $10M.
Best top-analyst consensus in the sector · Healthcare
About Nektar Therapeutics
- CEO: Howard W. Robin
- Employees: 63
- 455 Mission Bay Boulevard South, San Francisco, CA, 94158, US
- www.nektar.com
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Data from the stock’s TipRanks forecast page, read 25 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗